Presentations

      Pulmonary Neoplasia in Strain A Mice following Long-Term Tobacco Smoke Inhalation

      Lichtner, R. B.; Büttner, A.; Gebel, S.; van Overveld, F.; H-Haussmann, H-J. Haussmann.; Stinn, W.
      Conference date
      Nov 9, 2008
      Conference name
      American College of Toxicology (ACT) 2008
      Link to more information
      Link to more information
      Topic
      Summary

      Cigarette smoking is a major cause of lung cancer; however, it has been difficult to reproduce the tumorigenicity of cigarette smoke in preclinical animal models. Increased lung tumorigenicity has been reported in strain a (A/J) mice exposed for 5 months to cigarette mainstream smoke (MS) followed by 4 months without further exposure, but not in mice exposed for 9 months. Here we report on long-term (18-month) whole-body exposure (6 h/day, 5 d/wk) of male A/J mice to MS at total particulate matter (TPM) concentrations of 150 and 300 mg/m(3) or to fresh air (sham). Classical histopathological evaluation of step-serial sections identified nodular alveolar hyperplasias, bronchiolo-alveolar adenoma, and carcinoma in all groups. Lung tumor multiplicity calculated from the histopathological evaluation indicated increases of up to 5-fold for adenomas and 2-fold for carcinomas in the MS-exposed groups. Tumor nodules and surrounding normal lung tissue were microdissected from all groups. RNA array analysis of the normal lung tissue revealed the expression of several MS-exposure-related genes, such as those involved in oxidative stress, sustained inflammatory effects, and xenobiotic metabolizing pathways. MS exposure did not significantly change the K-RAS mutation pattern in the three “hot spot” codons (12, 13, and 61) in the tumor nodules. Our data show that long-term inhalation of MS in the A/J mouse is a promising model for cigarette-smoke-related lung cancer. Further investigations are warranted to qualify the biological relevance of the model. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.